Cargando…
Normal and tumor-derived organoids as a drug screening platform for tumor-specific drug vulnerabilities
Patient-derived tumor organoids can be predictive of patient’s treatment responses, and normal tissue-derived organoids allow for drug toxicity testing. Combining both types of organoids therefore enables screening for tumor-specific drug vulnerabilities. Here, we provide a detailed protocol for org...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752949/ https://www.ncbi.nlm.nih.gov/pubmed/35036959 http://dx.doi.org/10.1016/j.xpro.2021.101079 |